What is the recommended treatment for a facial herpes simplex infection?

Treatment of Facial Herpes Simplex Virus Infection

For facial HSV infection (herpes labialis), treat with oral valacyclovir, famciclovir, or acyclovir for 5-10 days, starting as early as possible during prodrome or at first sign of lesions. 1

First-Line Oral Antiviral Therapy

The standard treatment approach for orolabial HSV lesions involves oral antiviral agents:

• Valacyclovir: 1000 mg twice daily for 1 day, or 500 mg twice daily for 3 days 2
• Famciclovir: 1500 mg as a single dose, or 750 mg twice daily for 1 day 1
• Acyclovir: 200 mg five times daily, or 400 mg three times daily, or 800 mg twice daily for 5-10 days 1

Early initiation is critical—approximately 50% of episodes abort when therapy starts during prodrome/macule stages or within 6 hours of first symptoms. 2 Oral therapy is superior to topical preparations and should be the preferred route. 1, 3

Severe or Complicated Disease

For severe mucocutaneous HSV lesions, particularly in immunocompromised patients:

• IV acyclovir 5-10 mg/kg every 8 hours until lesions begin to regress 1
• Switch to oral therapy once improvement occurs and continue until complete healing 1
• Monitor renal function at initiation and once or twice weekly during IV treatment 1

Severe disease requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis) warrants IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days or until clinical resolution. 1

Treatment Failure and Resistance

Suspect acyclovir resistance if lesions fail to improve within 7-10 days of therapy initiation. 1

For acyclovir-resistant HSV:

• Obtain viral culture and susceptibility testing to confirm resistance 1
• IV foscarnet is the treatment of choice for confirmed resistance 1
• Topical alternatives (trifluridine, cidofovir, imiquimod) may be used for external lesions but require prolonged application for 21-28 days or longer 1, 4

Resistance develops primarily in immunocompromised patients receiving long-term antiviral therapy. 4

Suppressive Therapy for Recurrent Disease

For patients with frequent or severe recurrences (≥6 episodes per year):

• Daily suppressive therapy with oral acyclovir 400 mg twice daily, or famciclovir, or valacyclovir 1
• Suppressive therapy reduces recurrence frequency by at least 75% 1
• After 1 year of continuous therapy, discontinue to reassess recurrence rate 1
• Safety and efficacy documented for up to 5 years of daily use 1

Special Populations

HIV-infected patients:

• Use standard oral regimens but avoid short-course (1-3 day) therapy 1
• May require longer treatment duration (5-14 days) 1
• For suppressive therapy in HIV patients, use valacyclovir 500 mg twice daily (not once daily) 1

Pregnant patients:

• Acyclovir is the first-choice agent with established safety profile 1
• Episodic therapy can be offered during pregnancy 1
• Suppressive therapy not routinely recommended unless frequent severe recurrences 1

Important Caveats

• Topical acyclovir is substantially less effective than oral therapy and should be avoided 1
• Short-course therapy (1-3 days) should not be used in HIV-infected patients 1
• Antiviral therapy does not eradicate latent virus or prevent future recurrences after discontinuation 1
• Nausea and headache are occasional side effects; no routine laboratory monitoring needed unless significant renal impairment exists 1
• Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome reported only with high-dose (8 grams/day) valacyclovir, not at standard HSV treatment doses 1